

Silvia Buonamici

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11526858/publications.pdf>

Version: 2024-02-01

42
papers

7,518
citations

101543

36
h-index

265206

42
g-index

44
all docs

44
docs citations

44
times ranked

10557
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. <i>Cancer Cell</i> , 2015, 27, 617-630. | 16.8 | 449 |
| 2 | The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. <i>Journal of Experimental Medicine</i> , 2007, 204, 1825-1835. | 8.5 | 427 |
| 3 | Interfering with Resistance to Smoothed Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma. <i>Science Translational Medicine</i> , 2010, 2, 51ra70. | 12.4 | 416 |
| 4 | Molecular pathogenesis of T-cell leukaemia and lymphoma. <i>Nature Reviews Immunology</i> , 2008, 8, 380-390. | 22.7 | 396 |
| 5 | H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. <i>Nature Medicine</i> , 2018, 24, 497-504. | 30.7 | 391 |
| 6 | The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. <i>Nature</i> , 2017, 543, 733-737. | 27.8 | 389 |
| 7 | Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. <i>Cell Reports</i> , 2015, 13, 1033-1045. | 6.4 | 377 |
| 8 | A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. <i>Nature</i> , 2011, 473, 230-233. | 27.8 | 351 |
| 9 | Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. <i>Cell Reports</i> , 2018, 23, 282-296.e4. | 6.4 | 333 |
| 10 | Physiologic Expression of Sf3b1 K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. <i>Cancer Cell</i> , 2016, 30, 404-417. | 16.8 | 318 |
| 11 | Targeting the NF- κ B signaling pathway in Notch1-induced T-cell leukemia. <i>Nature Medicine</i> , 2007, 13, 70-77. | 30.7 | 315 |
| 12 | Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. <i>Nature Medicine</i> , 2016, 22, 672-678. | 30.7 | 301 |
| 13 | Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8120-8135. | 6.4 | 275 |
| 14 | CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. <i>Nature</i> , 2009, 459, 1000-1004. | 27.8 | 227 |
| 15 | A crucial requirement for Hedgehog signaling in small cell lung cancer. <i>Nature Medicine</i> , 2011, 17, 1504-1508. | 30.7 | 224 |
| 16 | Hedgehog Signaling Is Dispensable for Adult Hematopoietic Stem Cell Function. <i>Cell Stem Cell</i> , 2009, 4, 548-558. | 11.1 | 174 |
| 17 | EV11 induces myelodysplastic syndrome in mice. <i>Journal of Clinical Investigation</i> , 2004, 114, 713-719. | 8.2 | 174 |
| 18 | Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2016, 30, 750-763. | 16.8 | 173 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. <i>Cancer Cell</i> , 2018, 34, 225-241.e8. | 16.8 | 162 |
| 20 | Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. <i>Journal of Experimental Medicine</i> , 2008, 205, 1395-1408. | 8.5 | 157 |
| 21 | Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. <i>Blood</i> , 2002, 99, 443-449. | 1.4 | 133 |
| 22 | Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. <i>Nature Medicine</i> , 2013, 19, 1518-1523. | 30.7 | 127 |
| 23 | Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds. <i>Molecular Cell</i> , 2018, 70, 265-273.e8. | 9.7 | 126 |
| 24 | Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex. <i>Nature Communications</i> , 2017, 8, 15522. | 12.8 | 113 |
| 25 | Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS. <i>Cancer Cell</i> , 2018, 33, 386-400.e5. | 16.8 | 99 |
| 26 | Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. <i>Cell</i> , 2021, 184, 384-403.e21. | 28.9 | 94 |
| 27 | The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action. <i>Genes and Development</i> , 2018, 32, 309-320. | 5.9 | 89 |
| 28 | Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. <i>Nature Communications</i> , 2020, 11, 2089. | 12.8 | 83 |
| 29 | Discovery of NVP-EQ506, a Second-Generation Inhibitor of Smoothed. <i>ChemMedChem</i> , 2013, 8, 1261-1265. | 3.2 | 80 |
| 30 | Targeting splicing abnormalities in cancer. <i>Current Opinion in Genetics and Development</i> , 2018, 48, 67-74. | 3.3 | 72 |
| 31 | The role of EVI1 in normal and leukemic cells. <i>Blood Cells, Molecules, and Diseases</i> , 2003, 31, 206-212. | 1.4 | 71 |
| 32 | Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators. <i>Nature Communications</i> , 2019, 10, 137. | 12.8 | 65 |
| 33 | SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. <i>Nature Communications</i> , 2018, 9, 5378. | 12.8 | 60 |
| 34 | Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. <i>Cancer Discovery</i> , 2022, 12, 522-541. | 9.4 | 44 |
| 35 | Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2849-2861. | 4.1 | 41 |
| 36 | Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. <i>EBioMedicine</i> , 2019, 39, 215-225. | 6.1 | 41 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts. <i>Haematologica</i> , 2003, 88, 1221-8. | 3.5 | 40 |
| 38 | Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. <i>JCI Insight</i> , 2018, 3, . | 5.0 | 39 |
| 39 | EVI1 Abrogates Interferon- γ Response by Selectively Blocking PML Induction. <i>Journal of Biological Chemistry</i> , 2005, 280, 428-436. | 3.4 | 35 |
| 40 | Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients. <i>Blood Advances</i> , 2017, 1, 995-1000. | 5.2 | 23 |
| 41 | Knockdown of CCR7 or Its Ligands Causes a Loss of Central Nervous System Involvement in Notch1 Induced T-ALL. <i>Blood</i> , 2008, 112, 199-199. | 1.4 | 4 |
| 42 | Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. <i>Journal of Cell Biology</i> , 2008, 181, i16-i16. | 5.2 | 0 |